[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"traditional-chinese-medicine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:traditional-chinese-medicine":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,78,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100638172","moxibustion-for-nocturia-100638172",false,"NCT07598227","Moxibustion for Nocturia","Evaluation of the Efficacy and Safety of Acupoint Moxibustion for Nocturia: A Pilot Study","Inclusion Criteria:\n\n* Patients aged 40 years or older.\n* Experiencing two or more nocturia episodes per night.\n\nExclusion Criteria\n\n* Active urinary tract infection (UTI).\n* Poorly controlled diabetes mellitus (defined as HbA1c \\> 6.5%).\n* Presence of a neurogenic bladder caused by conditions such as multiple sclerosis, Parkinson's disease, stroke, spinal cord injury, or nerve damage resulting from major pelvic surgery.\n* Severe congestive heart failure (New York Heart Association \\[NYHA\\] functional class \\> II).\n* Use of other Traditional Chinese Medicine (TCM) therapies for nocturia symptoms within the past month (30 days).\n* Pregnant women.",true,"ALL","40 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Nocturia, the interruption of sleep due to nighttime voiding, severely compromises quality of life, emotional health, and overall well-being when occurring twice or more per night. Given that some patients experience inadequate responses to conventional Western therapies or harbor concerns about the long-term side effects of pharmaceuticals, many are turning to Traditional Chinese Medicine (TCM) for alternative solutions. This study utilized a randomized clinical trial design to investigate the efficacy and safety of acupoint moxibustion for nocturia.",[27,28,29,30],"Nocturia","Acupoint","Moxibustion","Traditional Chinese Medicine","RECRUITING","2026-05-17",{"date":34,"type":35},"2026-05-20","ACTUAL",{"date":37,"type":35},"2025-01-01",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Buddhist Tzu Chi General Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100587811","phase-1-efficacy-of-fuzheng-tongfu-jiedu-prescription-for-treating-gastrointestinal-dysfunction-associated-with-sepsis-100587811","NCT06933238","Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis","The Clinical Effect and Mechanism of Fuzheng Tongfu Jiedu Prescription Regulating Cell Pyrodeath in the Treatment of Gastrointestinal Dysfunction in Sepsis Based on mtDNA\u002FNLRP3\u002FCaspase-1\u002FGSDMD Signaling Pathway","FZTFJD","Inclusion Criteria:\n\n1. Clinical diagnosis of sepsis-induced gastrointestinal dysfunction with Acute AGI grade I-III.\n2. 50-90 years old, regardless of gender.\n3. Sequential Organ Failure Assessment (SOFA) score ≥ 2.\n4. Diagnosed with sepsis-induced gastrointestinal dysfunction within 24 hours.\n5. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. ICU length of stay ≤ 3 days (due to death, discharge, or transfer), rendering gastrointestinal function evaluation unfeasible.\n2. Patients with allergies or allergic constitution to the investigational herbal medications.\n3. Inability to measure intra-abdominal pressure or abdominal circumference due to obesity (weight \\> 150 kg), trauma, or surgical factors.\n4. Severe organic diseases: lower gastrointestinal bleeding, malignancies, cirrhosis, chronic renal failure (uremic stage), hematologic disorders, HIV, etc.\n5. History of gastrointestinal surgery.\n6. Long-term use of corticosteroids or immunosuppressants.\n7. Severe psychiatric disorders or inability to cooperate with trial protocols.\n8. Participation in other clinical trials within 30 days.\n9. Pregnant or lactating women.\n10. Participated in other clinical studies in the past 3 months.","50 Years","90 Years",{"count":55,"type":21},70,[57,58],"PHASE1","PHASE2","This study is a single-center, randomized, double-blind, placebo-controlled trial.",[61,62,30],"Sepsis Abdominal","Gastrointestinal Dysfunction",[64,65,66,67],"gastrointestinal dysfunction","sepsis","Traditional Chinese medicine","Fuzheng Tongfu Jiedu Decoction","NOT_YET_RECRUITING","2025-04-11",{"date":71,"type":35},"2025-04-18",{"date":73,"type":21},"2025-04-25",{"date":75,"type":21},"2026-06-30",{"name":77,"class":42},"Dongzhimen Hospital, Beijing",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":43},"100567817","respiratory-disease-cohort-studies-of-chinese-medicine-for-pulmonary-nodule-100567817","NCT06673121","Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule","Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule （RESEARCH-PN）","Inclusion Criteria:\n\n① Patients with pulmonary nodules and recommended for follow-up by MDT; ② Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n①Patients with metastatic pulmonary nodules; ②Patients with benign diseases such as pulmonary lymph nodes, hamartomas, sclerosing alveolar cell tumors, or nodules with obvious benign features such as calcification; ③Patients withserious heart, lung, liver and kidney diseases.",{"count":86,"type":21},5000,"OBSERVATIONAL","This study is a prospective multicenter cohort study that primarily evaluates the impact of traditional Chinese medicine treatment on pulmonary nodules",[90,91,30],"Pulmonary Nodule","Cohort Study",[93,94,30],"Pulmonary nodule","Cohort study","2024-11-01",{"date":97,"type":35},"2024-11-04",{"date":99,"type":35},"2024-01-03",{"date":101,"type":21},"2029-12-30",{"name":103,"class":42},"Third Affiliated Hospital of Henan University of Traditional Chinese Medicine",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100543611","buyuan-zhixiao-formula-in-the-treatment-of-elderly-patients-with-diabetes-and-multiple-metabolic-disorders-100543611","NCT06358118","Buyuan-zhixiao Formula in the Treatment of Elderly Patients With Diabetes and Multiple Metabolic Disorders","Clinical Research on Evidence Based Traditional Chinese Medicine for Elderly Diabetes Based on State Target Theory-Buyuan Zhixiao Fang in the Treatment of Elderly Patients With Diabetes and Multiple Metabolic Disorders: Study Protocol for a Multicenter, Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* 1.Age ≥65 years, irrespective of sex;\n* 2.Individuals who meet the Western medical diagnostic criteria for type 2 diabetes mellitus (T2DM) in the elderly, with a hemoglobin A1c level of ≥7.0% in the past three months;\n* 3.Compliance with the diagnostic criteria for abdominal obesity (waist circumference ≥90 cm for males and ≥85 cm for females);\n* 4.Conformity to the diagnostic standards for hypertension (systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg);\n* 5.A history of dyslipidemia, where lipid levels have not reached the general control standards for elderly individuals with T2DM following oral lipid-lowering therapy (statins\u002Fbile acid sequestrants): LDL cholesterol \\\u003C2.6 mmol\u002FL and\u002For triglycerides \\\u003C2.5 mmol\u002FL;\n* 6.Diagnosis of kidney deficiency and blood stasis according to traditional Chinese medicine, with the pattern type referring to the《Guidelines for Clinical Research of New Chinese Medicines》;\n* 7.Willingness to sign an informed consent document.\n\nExclusion Criteria:\n\n* 1.Exclusion of individuals who, within the past week, have experienced severe infections, acute cardiovascular or cerebrovascular events (such as acute cerebral infarction or myocardial infarction), significant trauma, acute pancreatitis, or other conditions that could precipitate stress-induced hyperglycemia. This also extends to those with concurrent endocrinopathies that may induce insulin resistance, such as Cushing's syndrome, hyperthyroidism, or pituitary growth hormone adenomas, as well as those currently receiving treatment with glucocorticoids or undergoing chemotherapy for malignancies.\n* 2.Exclusion of individuals with a history of neurological disorders or psychiatric conditions that could impair cognitive function, as well as those with a history of medication use for these conditions.\n* 3.Exclusion of individuals with severe complications of diabetes such as diabetic nephropathy in the uremic stage, or those with significant primary diseases of the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems, as well as individuals diagnosed with cancer.\n* 4.Exclusion of individuals with communication barriers that could affect the assessment of cognitive function, including severe impairments in speech, vision, and hearing.\n* 5.Individuals who have participated in other pharmacological clinical trials within the past month.\n* 6.Individuals who have insufficient understanding of this study, are unwilling to participate, or, based on the researchers' judgment, present a reduced likelihood of enrollment or poor compliance due to unstable work and living locations or other factors that could lead to loss to follow-up.","65 Years",{"count":113,"type":21},240,[24],"The primary objective of this clinical trial is to assess the clinical efficacy and safety of the Buyuan Zhixiao Formula in treating elderly patients with diabetes and multiple metabolic disorders exhibiting symptoms of renal deficiency and blood stasis. Furthermore, this study aims to intervene in high-risk factors to prevent arteriosclerosis and to investigate the clinical efficacy of the Buyuan Zhixiao Formula in the prevention and treatment of cognitive impairments.\n\nThe main questions it aims to answer are:\n\n1. What are the clinical effects of Buyuan Zhixiao Formula, including lowering blood sugar, lowering blood pressure, lowering lipids, and treating obesity?\n2. Can Buyuan Zhixiao Formula improve cognitive impairment in diabetes? Researchers compared Buyuan Zhixiao Formula with a placebo (a drug that looks similar but contains only 10% of the active ingredients) to see if the drug Buyuan Zhixiao Formula can treat elderly people with diabetes and multiple metabolic disorders.\n\nParticipants will:\n\n1. Take the drug Bu Yuan Zhi XiaoFormula or placebo every day for 6 months；Follow-up for 6 months；\n2. Check fasting blood sugar and 2-hour postprandial blood sugar every month; check HbA1c, blood lipids, vascular function, and cognitive impairment serum markers every 3 months;\n3. Conduct scores on TCM symptoms, cognitive ability, nutritional status and other scales and adverse events;\n4. Urine and serum samples were collected before and after treatment;",[117,118,119,30,120],"Diabete Mellitus","Aging","Metabolic Disorders","Randomized Controlled Trial","2024-06-02",{"date":123,"type":35},"2024-06-04",{"date":125,"type":21},"2024-07-06",{"date":127,"type":21},"2025-07-01",{"name":129,"class":42},"Qing Ni",6]